Clinical trials: Adenocarcinoma
Pancreas Cancer
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
- Trial name
- NCT05068752
- Testing
- Vemurafenib, Sorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HonorHealth Research Institute
Human Papillomavirus Infection, Cervical Cancer
Clinical Evaluation of Detection of High Risk HPV in Urine
Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer.
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Human Papilloma Virus, Negative for Intraepithelial Lesion or Malignancy
- Trial name
- Urine-hrHPV (NCT05210348)
- Where
- 3 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Clear Cell Renal Cell Carcinoma
Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy. This diagnosis is expensive, invasive and sometimes late. The development of a simple biological test for diagnosis is essential.
- Trial name
- PEP-C (NCT04053855)
- Testing
- Urinary sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
HCC - Hepatocellular Carcinoma
Sarcopenia and Systemic Therapy in HCC
This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.
- Trial name
- Sarco HCC (NCT06805552)
- Where
- Italy
- Volunteers
- 270 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Esophageal Cancer, Gastric Cancer
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or…
- Trial name
- NCT00003748
- Testing
- irinotecan hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastric Cancer
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive…
- Trial name
- RILOMET-2 (NCT02137343)
- Testing
- Rilotumumab, Cisplatin, Capecitabine
- Where
- 25 sites in Japan, South Korea
- Volunteers
- 34 people
- Sponsor
- Amgen
Breast Cancer, Ductal Carcinoma in Situ
Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity
This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes and tamoxifen.
- Trial name
- NCT00886535
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
Liver Cancer, Hepatocellular Carcinoma (HCC)
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
This is a research study to evaluate change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30), from baseline to 1 month post…
- Trial name
- NCT04933435
- Testing
- Quality of life questionnaires
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Duke University
Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
- Trial name
- DUO-CRC-NK-111 (NCT07589517)
- Testing
- EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Papillary Thyroid Cancer
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
Thyroid cancers that have spread beyond the neck are not curable. About 30,000 people worldwide die from thyroid cancer every year.
- Trial name
- NCT03469011
- Testing
- Imatinib Oral Tablet
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided implant radiation…
- Trial name
- NCT00450411
- Testing
- 125-Iodine, 103-palladium
- Where
- 17 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Radiation Therapy Oncology Group
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Lung
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed…
- Trial name
- NCT01218516
- Testing
- Farletuzumab, Carboplatin, Paclitaxel
- Where
- 93 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Morphotek
Prostate Cancer
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor…
- Trial name
- NCT00217516
- Testing
- selenium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Adenocarcinoma of Gastric, Adenocarcinoma of Esophagogastric Junction
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction
- Trial name
- NCT07406984
- Testing
- IM96 CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Digestive Cancer
A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan
This study is to determine the Maximal Tolerated Dose (MTD), the Dose Limitant Toxicities (DLTs) and the safety profile of S-1 combined with fixed doses of Irinotecan (SIRI schedule) and fixed doses of Irinotecan and Oxaliplatin…
- Trial name
- SIRINOX (NCT02387138)
- Testing
- S-1, Irinotecan, Oxaliplatin
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Carcinoma, Hepatocellular
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
This multicenter, open-label study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicities of onartuzumab as single agent or in combination with sorafenib in participants with advanced hepatocellular…
- Trial name
- NCT01897038
- Testing
- Onartuzumab, Sorafenib
- Where
- 10 sites in United States, Hong Kong and 2 more
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Liver Cancer
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of…
- Trial name
- NCT00093548
- Testing
- alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant
- Sponsor
- Jonsson Comprehensive Cancer Center
Urothelial Cancer, Bladder Cancer
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare.
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms
- Trial name
- NCT04923178
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- National Cancer Institute (NCI)